Novel recombinant human tumor necrosis factor (Guangdong Taihe Biotech/Shanghai Saida Bioteh)

新型重组人肿瘤坏死因子（上海赛达生物/广东泰禾生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameNovel recombinant human tumor necrosis factor (Guangdong Taihe Biotech/Shanghai Saida Bioteh)
Drug Alias NamermhTNF纳科思Recombination Mutant Human Tumor Necrosis Factor
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionTumor necrosis factor receptor agonists
TargetsTumor necrosis factor receptor
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2003/07/23
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGuangdong Taihe Medicine Technology Co LtdShanghai Pudong Xiangju Biotechnology Co., Ltd.
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Pudong Xiangju Biotechnology Co., Ltd.
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeL01
Related LinksN/A